Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CATX Perspective Therapeutics	$3.36 -0.6%	$3.79	$1.60 ▼ $16.31	$249.52M	1.17	927,790 shs	456,073 shs
INFU InfuSystem	$10.78 +0.5%	$7.20	$4.61 ▼ $11.04	$220.19M	1.81	176,357 shs	314,045 shs
NSPR InspireMD	$2.44 +0.8%	$2.42	$1.99 ▼ $3.80	$100.97M	0.6	103,146 shs	32,601 shs
OBLN Obalon Therapeutics	$9.20 -4.2%	$4.22	$0.66 ▼ $10.77	$92.20M	-1.23	7.68 million shs	35,590 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CATX Perspective Therapeutics	0.00%	-8.70%	-12.50%	+30.74%	-78.00%
INFU InfuSystem	0.00%	+12.64%	+92.50%	+86.51%	+66.62%
NSPR InspireMD	0.00%	+2.52%	-12.54%	-3.56%	-14.08%
OBLN Obalon Therapeutics	-4.17%	-20.07%	+263.64%	+87.37%	+5,839.32%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CATX Perspective Therapeutics	1.4899 of 5 stars	3.6	1.0	0.0	0.0	2.4	0.8	0.0
INFU InfuSystem	2.7278 of 5 stars	1.0	5.0	0.0	0.0	2.8	3.3	2.5
NSPR InspireMD	3.3245 of 5 stars	3.5	5.0	0.0	0.0	0.6	4.2	0.6
OBLN Obalon Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CATX Perspective Therapeutics	3.18	Buy	$12.56	273.68% Upside
INFU InfuSystem	4.00	Strong Buy	$12.50	15.96% Upside
NSPR InspireMD	3.00	Buy	$4.50	84.43% Upside
OBLN Obalon Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest OBLN, CATX, INFU, and NSPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/22/2025	INFU InfuSystem	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
7/21/2025	INFU InfuSystem	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/12/2025	CATX Perspective Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/23/2025	CATX Perspective Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $12.00
6/23/2025	CATX Perspective Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00
6/3/2025	CATX Perspective Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$15.00 ➝ $16.00

(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	$2.67 per share	N/A
INFU InfuSystem	$139.89M	1.57	$0.84 per share	12.79	$2.47 per share	4.36
NSPR InspireMD	$7.07M	14.41	N/A	N/A	$1.83 per share	1.33
OBLN Obalon Therapeutics	$1.59M	57.99	N/A	N/A	$0.60 per share	15.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CATX Perspective Therapeutics	-$46.51M	N/A	0.00	N/A	N/A	-4,096.66%	-27.40%	-23.16%	11/11/2025 (Estimated)
INFU InfuSystem	$870K	$0.23	179.70	34.77	N/A	1.12%	2.78%	1.41%	N/A
NSPR InspireMD	-$19.92M	-$0.83	N/A	N/A	N/A	-413.96%	-69.42%	-57.68%	N/A
OBLN Obalon Therapeutics	-$12.33M	N/A	N/A	∞	N/A	-776.76%	-161.38%	-83.58%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	N/A
INFU InfuSystem	N/A	N/A	N/A	N/A	N/A
NSPR InspireMD	N/A	N/A	N/A	N/A	N/A
OBLN Obalon Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CATX Perspective Therapeutics	N/A	9.60	9.60
INFU InfuSystem	0.50	1.98	1.59
NSPR InspireMD	N/A	6.39	6.05
OBLN Obalon Therapeutics	N/A	1.86	1.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CATX Perspective Therapeutics	54.66%
INFU InfuSystem	71.13%
NSPR InspireMD	44.78%
OBLN Obalon Therapeutics	18.64%

Insider Ownership

Company	Insider Ownership
CATX Perspective Therapeutics	3.72%
INFU InfuSystem	11.40%
NSPR InspireMD	34.06%
OBLN Obalon Therapeutics	8.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CATX Perspective Therapeutics	70	74.26 million	65.21 million	Optionable
INFU InfuSystem	410	20.43 million	19.10 million	Optionable
NSPR InspireMD	50	41.72 million	18.33 million	Optionable
OBLN Obalon Therapeutics	2	10.02 million	N/A	Not Optionable

OBLN, CATX, INFU, and NSPR Headlines

Recent News About These Companies

InterWest Management Partners X, LLC's Net Worth

August 4, 2024 | benzinga.com

Obalon Therapeutics, Inc.

February 25, 2024 | thestreet.com

Spero Therapeutics Inc.

February 6, 2024 | wsj.com

Intragastric Balloon Market Growth and Forecast till 2031

March 28, 2023 | marketwatch.com

Intragastric Balloons Market to Grow with a Significant CAGR During the forecast period 2022-2028| Exclusive Report Spread Across 149 Pages

August 17, 2022 | marketwatch.com

Renovare Environmental Inc (RENO)

January 5, 2022 | investing.com

Understanding Atara Biotherapeutics's Unusual Options Activity

August 10, 2021 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

OBLN, CATX, INFU, and NSPR Company Descriptions

Perspective Therapeutics NYSE:CATX

$3.36 -0.02 (-0.59%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$3.41 +0.05 (+1.37%)

As of 08/29/2025 08:00 PM Eastern

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

InfuSystem NYSE:INFU

$10.78 +0.05 (+0.47%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$10.78 0.00 (-0.05%)

As of 08/29/2025 07:55 PM Eastern

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

InspireMD NYSE:NSPR

$2.44 +0.02 (+0.83%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$2.44 0.00 (0.00%)

As of 08/29/2025 06:30 PM Eastern

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

Obalon Therapeutics NASDAQ:OBLN

Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallowable capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. Obalon Therapeutics, Inc. was incorporated in 2008 and is headquartered in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time